FASLG and colonic neoplasm: Vorinostat in combination with chemotherapeutic agent decitabine increased sensitivity of Fas ligand (FasL)-induced apoptosis and CTL immunotherapy via promotion of CD8+ T cells in colon cancer cells (43).